Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | CRHBP | P24387 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692060 | 0.77 | TRPA1 (0.41) | TRPA1CYP1A2CYP2D6 | |
| SCHEMBL3092641 | 0.68 | TRPA1 (0.41) | TRPA1CYP1A2CYP2D6LMNAKDM4E | |
| SCHEMBL2514743 | 0.67 | TRPA1 (0.39) | TRPA1ITGB2ICAM1ITGALLMNA | |
| SCHEMBL16399898 | 0.67 | ABCG2 (0.42) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL30587667 | 0.66 | TRPA1 (0.47) | TRPA1CYP1A2CYP2D6LMNAHTT | |
| SCHEMBL19518260 | 0.62 | ITGB2 (0.46) | TRPA1ITGB2ICAM1ITGALCYP1A2 | |
| SCHEMBL30218263 | 0.62 | TRPA1 (0.32) | TRPA1MAPT | |
| SCHEMBL29394860 | 0.62 | TRPA1 (0.32) | TRPA1MAPT | |
| SCHEMBL2500373 | 0.62 | TRPA1 (0.34) | TRPA1CYP1A2CYP2D6LMNACRHBP | |
| SCHEMBL6804256 | 0.62 | TRPA1 (0.43) | TRPA1CYP1A2CYP2D6LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1064 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801522-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2021-04-14 | — | — | EP | claimed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| US-20060106059-A1 | Melanocortin receptor ligands | MAZUR WIESLAW A | 2006-05-18 | — | — | US | claimed |
| EP-1390361-A4 | MELANOCORTIN RECEPTOR LIGANDS | PROCTER & GAMBLE (US) | 2005-10-05 | — | — | EP | claimed |
| US-6911447-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-28 | — | — | US | claimed |
| US-20040224985-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2004-11-11 | — | — | US | claimed |
| CN-1543334-A | Oxidation hair dye agent comprising 3-aminophenol derivative and novel 3-aminophenol derivative | P&G | 2004-11-03 | — | — | CN | claimed |
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | claimed |
| EP-1390361-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | claimed |
| US-20030109556-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-06-12 | — | — | US | claimed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | claimed |
| EP-1280782-A2 | NOVEL BENZOXAZINONES AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA MODULATORS AND METHOD OF TREATMENT | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-02-05 | — | — | EP | claimed |
| WO-2002085925-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2001087860-A2 | NOVEL BENZOXAZINONES AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA MODULATORS AND METHOD OF TREATMENT | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | claimed |
| CN-1074413-C | Novel benzimidazole derivatives having CGMP-phosphodisterase inhibiting activity | OTSUKA PHARMA CO LTD (JP) | 2001-11-07 | — | — | CN | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| CN-1158129-A | Novel benzimidazole derivatives having CGMP-phosphodisterase inhibiting activity | OTSUKA PHARMA CO LTD (JP) | 1997-08-27 | — | — | CN | claimed |
| CN-115210273-B | Process for controlling the formation of ziegler-natta procatalyst particles and use for olefin polymerization | 布拉斯科美国公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240174776-A1 | SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | W.R. GRACE & CO.-CONN. (US) | 2024-05-30 | — | — | US | disclosed |
| US-11925689-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240043446-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | INTERVET INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4308615-A1 | SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | W. R. Grace & Co.-Conn (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355546-A | Spherical catalyst component for olefin polymerization | 格雷斯公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-3464391-B1 | NON-PHTHALATE DONOR FOR POLYOLEFIN CATALYSTS | BRASKEM AMERICA INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230382938-A1 | ELECTROCHROMIC DEVICES HAVING A BUFFER SYSTEM | GENTEX CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| CN-110770226-B | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023205262-A1 | ELECTROCHROMIC DEVICES HAVING A BUFFER SYSTEM | GENTEX CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4259636-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | Intervet International B.V. (NL) | 2023-10-18 | — | — | EP | disclosed |
| CN-111743901-B | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11739131-B2 | Growth differentiation factor 15 (GDF-15) polypeptides | AMGEN INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023159179-A1 | ELECTROCHEMICAL COMPOUNDS FOR LOW CURRENT ELECTROCHROMIC DEVICES | GENTEX CORPORATION (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230266630-A1 | ELECTROCHROMIC COMPOUNDS FOR MEMORY ELECTROCHROMIC DEVICES | GENTEX CORPORATION (US) | 2023-08-24 | — | — | US | disclosed |
| CN-116600807-A | Insect repellent compound comprising thienopyridine structure | 英特维特国际股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023147021-A1 | OLEFIN POLYMERIZATION CATALYST COMPRISING MAGNESIUM, TITANIUM, AN EPOXY COMPOUND AND AN INTERNAL ELECTRON DONOR, SUCH AS A 1,2-PHENYLENE DIBENZOATE-BASED COMPOUND | W.R. GRACE & CO.-CONN. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3054937-B1 | SPRAY DRY FORMULATIONS | PULMOKINE INC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113574094-B | UV curable composition for stain resistance | 巴斯夫欧洲公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230220239-A1 | UV CURABLE COMPOSITIONS FOR DIRT PICK-UP RESISTANCE | BASF SE (DE) | 2023-07-13 | — | — | US | disclosed |
| US-11692090-B2 | Dielectric cross-linked fluoropolymer | DAIKIN AMERICA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-113056526-B | Aqueous coating composition | 巴斯夫欧洲公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-110300578-B | Compounds for the treatment of respiratory diseases in cattle or pigs | 英特维特国际股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-115210273-A | Method for controlling the formation of ziegler-natta precatalyst particles and use for olefin polymerization | 布拉斯科美国公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110325603-B | Method for preparing functional aqueous dispersions | 巴斯夫欧洲公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022197491-A1 | SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | W.R. GRACE & CO.-CONN. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| CN-114846014-A | Insect repellent compounds comprising azaindole structures | 英特维特国际股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114845994-A | Insect-repellent compound comprising quinoline structure | 英特维特国际股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11396573-B2 | Hydrophobic block—random block copolymer emulsion polymer stabilizers | BASF SE | 2022-07-26 | — | — | US | disclosed |
| EP-4028433-A1 | METHODS OF CONTROLLING ZIEGLER-NATTA PRE-CATALYST PARTICLES FORMATION AND USE FOR OLEFIN POLYMERIZATION | Braskem America, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-110573535-B | Electron donors for ziegler-natta precatalyst preparation and catalyst systems for olefin polymerization | 格雷斯公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11370854-B2 | Non-phthalate donor for polyolefin catalysts | BRASKEM AMERICA, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022122988-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | INTERVET INTERNATIONAL B.V. (NL) | 2022-06-16 | — | — | WO | disclosed |
| US-11332557-B2 | Methods of controlling ziegler-natta pre-catalyst particles formation and use for olefin polymerization | BRASKEM AMERICA, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11291981-B2 | Boron-based electron donors for Ziegler-Natta catalyst systems | BRASKEM AMERICA, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3941970-A1 | UV CURABLE COMPOSITIONS FOR DIRT PICK-UP RESISTANCE | BASF SE (DE) | 2022-01-26 | — | — | EP | disclosed |
| US-11213588-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214633-B2 | Ziegler-Natta catalyst systems and methods of controlling particle size | BRASKEM AMERICA, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| CN-109790238-B | Non-phthalate donors for polyolefin catalysts | 布拉斯科美国公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20210388195-A1 | WATERBORNE COATING COMPOSITIONS | BASF SE (DE) | 2021-12-16 | — | — | US | disclosed |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11168158-B2 | Electron donors for ziegler-natta precatalyst preparation and catalyst system for olefin polymerization | BRASKEM AMERICA, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| CN-110229253-B | LED curable low mobility photoinitiators | IGM集团公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113574094-A | UV curable composition for stain resistance | 巴斯夫欧洲公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113527512-A | Growth differentiation factor 15(GDF-15) constructs | 美国安进公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3884001-A2 | WATERBORNE COATING COMPOSITIONS | BASF SE (DE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INC. (US) | 2021-09-23 | — | — | US | disclosed |
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| US-11084828-B2 | Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease | Ganget BioTekpharma, LLC (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3529325-B1 | METHODS FOR PREPARATION OF FUNCTIONAL WATERBORNE DISPERSIONS | BASF SE (DE) | 2021-06-30 | — | — | EP | disclosed |
| CN-113056526-A | Aqueous coating composition | 巴斯夫欧洲公司 | 2021-06-29 | — | — | CN | disclosed |
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-105980400-B | Growth differentiation factor 15(GDF-15) constructs | 美国安进公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3810571-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810576-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| CN-107849042-B | Bicyclic heterocyclic derivatives | 默克专利股份公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-3798238-A1 | LED-CURABLE LOW MIGRATION PHOTOINITIATORS | IGM Group B.V. (NL) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021050248-A1 | METHODS OF CONTROLLING ZIEGLER-NATTA PRE-CATALYST PARTICLES FORMATION AND USE FOR OLEFIN POLYMERIZATION | BRASKEM AMERICA, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210079051-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210070896-A1 | ZIEGLER-NATTA CATALYST SYSTEMS AND METHODS OF CONTROLLING PARTICLE SIZE | BRASKEM AMERICA, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070899-A1 | METHODS OF CONTROLLING ZIEGLER-NATTA PRE-CATALYST PARTICLES FORMATION AND USE FOR OLEFIN POLYMERIZATION | BRASKEM AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210032453-A1 | DIELECTRIC CROSS-LINKED FLUOROPOLYMER | DAIKIN AMERICA, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| US-10894814-B2 | Growth differentiation factor 15 (GDF-15) constructs | AMGEN INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3763734-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | Amgen Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10864276-B2 | Activated polyoxazolines and conjugates and compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| CN-111743901-A | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| CN-107567466-B | LED curable low mobility photoinitiators | IGM集团公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3717533-A1 | HYDROPHOBIC BLOCK RANDOM BLOCK COPOLYMER EMULSION POLYMER STABILIZERS | BASF SE (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020190833-A1 | UV CURABLE COMPOSITIONS FOR DIRT PICK-UP RESISTANCE | BASF SE (DE) | 2020-09-24 | — | — | WO | disclosed |
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| EP-3027642-B1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN INC (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3683228-A2 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES | Amgen Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200223958-A1 | NON-PHTHALATE DONOR FOR POLYOLEFIN CATALYSTS | W.R. GRACE & CO.-CONN. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| EP-3668643-A1 | BORON-BASED ELECTRON DONORS FOR ZIEGLER-NATTA CATALYST SYSTEMS | Braskem America, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3012259-B1 | FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10662267-B2 | Non-phthalate donor for polyolefin catalysts | W.R. GRACE & CO. -CONN. (US) | 2020-05-26 | — | — | US | disclosed |
| CN-106132403-B | Spray-dried formulations | 普尔莫凯恩股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | INTERVET INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-10584188-B2 | LED-curable low migration photoinitiators | IGM MALTA LIMITED (MT) | 2020-03-10 | — | — | US | disclosed |
| CN-110770226-A | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200010586-A1 | ELECTRON DONORS FOR ZIEGLER-NATTA PRECATALYST PREPARATION AND CATALYST SYSTEM FOR OLEFIN POLYMERIZATION | W. R. GRACE & CO.-CONN. | 2020-01-09 | — | — | US | disclosed |
| WO-2020002234-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INTERNATIONAL B.V. (NL) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002238-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INTERNATIONAL B.V. (NL) | 2020-01-02 | — | — | WO | disclosed |
| CN-110573535-A | Electron donors for ziegler-natta precatalyst preparation and catalyst systems for olefin polymerization | 格雷斯公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190352256-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | AMGEN INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190315822-A1 | Growth Differentiation Factor 15 (GDF-15) Polypeptides | AMGEN INC. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2019199542-A1 | ACRYLIC COPOLYMERS FOR WET PRESSURE-SENSITIVE ADHESIVES | BASF SE (DE) | 2019-10-17 | — | — | WO | disclosed |
| US-20190270831-A1 | NON-PHTHALATE DONOR FOR POLYOLEFIN CATALYSTS | W. R. GRACE & CO. - CONN. | 2019-09-05 | — | — | US | disclosed |
| EP-3529325-A1 | METHODS FOR PREPARATION OF FUNCTIONAL WATERBORNE DISPERSIONS | BASF SE (DE) | 2019-08-28 | — | — | EP | disclosed |
| US-20190248761-A1 | NON-SELECTIVE KINASE INHIBITORS | PULMOKINE INC (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190241763-A1 | METHODS FOR PREPARATION OF FUNCTIONAL WATERBORNE DISPERSIONS | BASF SE (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-2585455-B1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | UNIV CALIFORNIA (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233550-A1 | LED-CURABLE LOW MIGRATION PHOTOINITIATORS | BASF SE (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10344037-B2 | Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease | Canget BioTek Pharma LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-10336798-B2 | Growth differentiation factor 15 (GDF-15) polypeptides | AMGEN INC. | 2019-07-02 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10301399-B2 | LED-curable low migration photoinitiators | IGM MALTA LIMITED (MT) | 2019-05-28 | — | — | US | disclosed |
| US-20190134208-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS (AL), INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-3265465-B1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10246438-B2 | Non-selective kinase inhibitors | PULMOKINE, INC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10227295-B2 | Selective histone deactylase 6 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190070301-A1 | ACTIVATED POLYOXAZOLINES AND CONJUGATES AND COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS (AL), INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2019036376-A1 | BORON-BASED ELECTRON DONORS FOR ZIEGLER-NATTA CATALYST SYSTEMS | BRASKEM AMERICA, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190046965-A1 | BORON-BASED ELECTRON DONORS FOR ZIEGLER-NATTA CATALYST SYSTEMS | BRASKEM AMERICA, INC. | 2019-02-14 | — | — | US | disclosed |
| US-10166294-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180354918-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2018-12-13 | — | — | US | disclosed |
| US-10086084-B2 | Activated polyoxazolines and conjugates and compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| WO-2018164658-A1 | ELECTRON DONORS FOR ZIEGLER-NATTA PRECATALYST PREPARATION AND CATALYST SYSTEM FOR OLEFIN POLYMERIZATION | W.R. GRACE & CO.-CONN. (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20180193336-A1 | SPRAY DRY FORMULATIONS | PULMOKINE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180170944-A1 | USE OF THE FL-ONE HUNDRED EIGHTEEN CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL-ONE HUNDRED EIGHTEEN DERIVATIVES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA, LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180162837-A1 | NON-SELECTIVE KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9988381-B2 | Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| EP-3316968-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018075656-A1 | METHODS FOR PREPARATION OF FUNCTIONAL WATERBORNE DISPERSIONS | BASF SE (DE) | 2018-04-26 | — | — | WO | disclosed |
| US-9925184-B2 | Spray-dry formulations | PULMOKINE, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180079790-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN INC. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-1175383-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PROD INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180051021-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2018-02-22 | — | — | US | disclosed |
| WO-2018017896-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2018-01-25 | — | — | WO | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20180016364-A1 | LED-CURABLE LOW MIGRATION PHOTOINITIATORS | IGM MALTA LIMITED (MT) | 2018-01-18 | — | — | US | disclosed |
| EP-3265465-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | Amgen Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9862752-B2 | Growth differentiation factor 15 (GDF-15) constructs | AMGEN INC. (US) | 2018-01-09 | — | — | US | disclosed |
| CN-107531705-A | Bicyclic one sulfonamide compound | 美国安进公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20170369428-A1 | SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3242898-A1 | LED-CURABLE LOW MIGRATION PHOTOINITIATORS | IGM Malta Limited (MT) | 2017-11-15 | — | — | EP | disclosed |
| EP-2958902-B1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9815815-B2 | Non-selective kinase inhibitors | PULMOKINE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170291929-A1 | Growth Differentiation Factor 15 (GDF-15) Polypeptides | AMGEN INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2970237-B1 | HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9758495-B2 | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9751832-B2 | Selective histone deactylase 6 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| CN-106986856-A | It is used as 4 { [(ylmethyl of pyridine 3) amino carbonyl] amino } Benzosulfone derivatives of the NAMPT inhibitor for treating diseases such as cancer | 福马TM有限责任公司 | 2017-07-28 | — | — | CN | disclosed |
| US-9714276-B2 | Growth differentiation factor 15 (GDF-15) polypeptides | AMGEN INC. (US) | 2017-07-25 | — | — | US | disclosed |
| EP-3042922-B1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170173171-A1 | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same | SERINA THERAPEUTICS (AL), INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-106715443-A | Use of FL118 mother nucleus chemical structure platform to generate FL118 derivatives for treating human diseases | 坎格特生物技术制药有限责任公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-106632091-A | Application of quinazoline compounds in regulation of neural stem cell proliferation and differentiation | 中国科学院上海药物研究所 | 2017-05-10 | — | — | CN | disclosed |
| CN-104093715-B | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | 埃科特莱茵药品有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-3122754-A2 | USE OF THE FL118 CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL118 DERIVATIVES FOR TREATMENT OF HUMAN DISEASE | Canget Biotekpharma, LLC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| US-9540375-B2 | Kappa opioid receptor effectors and uses thereof | UNIVERSITY OF KANSAS (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2017001661-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160340298-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS, INC. | 2016-11-24 | — | — | US | disclosed |
| EP-2760845-B1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160317673-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | SERINA THERAPEUTICS (AL), INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9458152-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160257685-A1 | KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-09-08 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160235742-A1 | SPRAY DRY FORMULATIONS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-3054937-A1 | SPRAY DRY FORMULATIONS | Zisman, Lawrence, S. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403760-B2 | Compounds | AVANTI POLAR LIPIDS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2016111923-A1 | LED-CURABLE LOW MIGRATION PHOTOINITIATORS | BASF SE (DE) | 2016-07-14 | — | — | WO | disclosed |
| EP-3042922-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | Serina Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160185716-A1 | SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2016-06-30 | — | — | US | disclosed |
| US-9376425-B2 | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160168213-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168116-A1 | IRE-1alpha Inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2016-06-16 | — | — | US | disclosed |
| EP-3030235-A1 | FORMULATIONS CONTAINING GAMMA SECRETASE MODULATORS | NeuroGenetic Pharmaceuticals, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-3027642-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN, INC. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9359326-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9345703-B2 | Kappa opioid receptor effectors and uses thereof | UNIVERSITY OF KANSAS (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346798-B2 | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137640-A1 | FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO. LTD. (CN) | 2016-05-19 | — | — | US | disclosed |
| EP-3012259-A1 | FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-04-27 | — | — | EP | disclosed |
| EP-3008057-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | Amgen Inc. (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-3007689-A1 | NON-SELECTIVE KINASE INHIBITORS | Zisman, Lawrence, S. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| EP-2669313-B1 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9284411-B2 | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds | SERINA THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2988738-A2 | THERAPEUTIC INDICATIONS OF KINASE INHIBITORS | Zisman, Lawrence, S. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160046626-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160039774-A1 | HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2520561-B1 | IRE-1A Inhibitors | MANNKIND CORP (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9257699-B2 | Sulfur cathode hosted in porous organic polymeric matrices | UCHICAGO ARGONNE, LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160024001-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS INC (US) | 2016-01-28 | — | — | US | disclosed |
| CN-105283440-A | Novel compounds | AVANTI POLAR LIPIDS INC | 2016-01-27 | — | — | CN | disclosed |
| US-9241942-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160017094-A1 | Ring Opening Of Oxazolines At High Temperature In A Continuous Process | BASF SE (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970237-A1 | HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970588-A1 | RING OPENING OF OXAZOLINES AT HIGH TEMPERATURE IN A CONTINUOUS PROCESS | BASF SE (DE) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970113-A1 | NOVEL COMPOUNDS | Avanti Polar Lipids Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002185-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2958902-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| CN-103221404-B | Can be used as the unsaturated nitrogen heterogeneous ring compound of PDE10 inhibitor | AMGEN INC. (US) | 2015-12-16 | — | — | CN | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150353527-A1 | NON-SELECTIVE KINASE INHIBITORS | PULMOKINE, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150352111-A1 | Therapeutic Indications of Kinase Inhibitors | PULMOKINE, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9178249-B2 | Electrode stabilizing materials | UCHICAGO ARGONNE, LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-9169354-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150273074-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | SERINA THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015148415-A2 | USE OF THE FL118 CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL118 DERIVATIVES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA, LLC (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| US-9108941-B2 | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2900064-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | Zoetis LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9079902-B2 | Heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150190526-A1 | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same | SERINA THERAPEUTICS INC (US) | 2015-07-09 | — | — | US | disclosed |
| US-9051311-B2 | Sulfamide sodium channel inhibitors | AMGEN INC. (US) | 2015-06-09 | — | — | US | disclosed |
| CN-101611053-B | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND LTD | 2015-06-03 | — | — | CN | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| US-20150111884-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | ZOETIS SERVICES LLC | 2015-04-23 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2015054574-A1 | SPRAY DRY FORMULATIONS | ZISMAN LAWRENCE S (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2637665-B1 | DEXAMETHASONE COMBINATION THERAPY | UNIV TEXAS (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2849756-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | Novartis AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20150080538-A1 | Polyoxazolines with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds | SERINA THERAPEUTICS (AL), INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150079658-A1 | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same | SERINA THERAPEUTICS INC (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| EP-2357184-B1 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8956669-B2 | Anticancer and antimicrobial compounds from antarctic extremophilic microorgansims | THE UAB RESEARCH FOUNDATION (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2015021191-A1 | FORMULATIONS CONTAINING GAMMA SECRETASE MODULATORS | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| US-20150045353-A1 | FORMULATIONS CONTAINING GAMMA SECRETASE MODULATORS, METHODS FOR PREPARATION AND DELIVERY THEREOF | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952149-B2 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS LLC (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2015017710-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | AMGEN INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017546-A1 | SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-20140378665-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES | AMGEN INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140378422-A1 | Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| WO-2014201173-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371227-A1 | KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-2809312-A1 | COMBINATION OF A RTK INHIBITOR WITH AN ANTI - ESTROGEN AND USE THEREOF FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2014-12-10 | — | — | EP | disclosed |
| CN-104204218-A | Growth differentiation factor 15 (GDF-15) polypeptides | AMGEN INC | 2014-12-10 | — | — | CN | disclosed |
| EP-2807266-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES | Amgen Inc. (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8883211-B2 | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds | SERINA THERAPEUTICS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| WO-2014153147-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150799-A1 | RING OPENING OF OXAZOLINES AT HIGH TEMPERATURE IN A CONTINUOUS PROCESS | BASF SE (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151863-A1 | HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | disclosed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140275591-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2776405-A1 | 2-THIOPYRIMIDINONES | Pfizer Inc (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140255794-A1 | SULFUR CATHODE HOSTED IN POROUS ORGANIC POLYMERIC MATRICES | UCHICAGO ARGONNE LLC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256707-A1 | Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014130470-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| EP-2762475-A1 | Pharmaceutically acceptable salts of quinolinone compounds and their medical use | Novartis Vaccines and Diagnostics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2760845-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014110200-A1 | NON-SELECTIVE KINASE INHIBITORS | ZISMAN LAWRENCE S (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014110198-A2 | THERAPEUTIC INDICATIONS OF KINASE INHIBITORS | ZISMAN LAWRENCE S (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-2750670-A1 | PI3K INHIBITOR FOR USE IN THE TREATMENT OF BONE CANCER OR FOR PREVENTING METASTATIC DISSEMINATION PRIMARY CANCER CELLS INTO THE BONE | Novartis AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| CN-103917529-A | 2-thiopyrimidinones | PFIZER | 2014-07-09 | — | — | CN | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2744805-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | Amgen Inc. (US) | 2014-06-25 | — | — | EP | disclosed |
| CN-102149749-B | Polyoxazolines with inert end groups, polyoxazolines prepared from protected initiator groups and related compounds | SERINA THERAPEUTICS INC | 2014-06-25 | — | — | CN | disclosed |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. | 2014-06-05 | — | — | US | disclosed |
| EP-2465857-B1 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-8741923-B2 | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis | MERCK SERONO SA (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| CN-103764130-A | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone | NOVARTIS AG | 2014-04-30 | — | — | CN | disclosed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| CN-103717586-A | Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC | 2014-04-09 | — | — | CN | disclosed |
| US-20140088093-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | ZOETIS LLC (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140066577-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | SERINA THERAPEUTICS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014035872-A1 | TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| EP-2694491-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8614253-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2669313-A1 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | Serina Therapeutics, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130310352-A1 | DEXAMETHASONE COMBINATION THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013173283-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013173382-A1 | BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8551661-B2 | Long life lithium batteries with stabilized electrodes | UCHICAGO ARGONNE, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-1885187-B1 | METHODS FOR TREATING DRUG RESISTANT CANCER | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2637665-A1 | DEXAMETHASONE COMBINATION THERAPY | Board Of Regents, The University Of Texas System (US) | 2013-09-18 | — | — | EP | disclosed |
| CN-103313714-A | Dexamethasone combination therapy | UNIV TEXAS | 2013-09-18 | — | — | CN | disclosed |
| WO-2013134518-A1 | SULFAMIDE SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2235090-B1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| WO-2013122897-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013116293-A1 | COMBINATION OF A RTK INHIBITOR WITH AN ANTI - ESTROGEN AND USE THEREOF FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-08-08 | — | — | WO | disclosed |
| US-8501899-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013113008-A1 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES | AMGEN INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| EP-2620439-A1 | 8-pyrazinyl-S-spiropyrimidinetrione-oxazinoquinoline derivatives as antibacterial agents | PAH USA 15 LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
| EP-1608369-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2261223-B1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013068875-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| EP-2585455-A2 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | The Regents of The University of California (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130101622-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| CN-101389622-B | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG | 2013-04-17 | — | — | CN | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2013049250-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2569302-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen, Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569300-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569299-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569306-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013030368-A1 | PI3K INHIBITOR FOR USE IN THE TREATMENT OF BONE CANCER OR FOR PREVENTING METASTATIC DISSEMINATION PRIMARY CANCER CELLS INTO THE BONE | NOVARTIS AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013025883-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2012-12-20 | — | — | US | disclosed |
| EP-2532643-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-12-12 | — | — | EP | disclosed |
| CN-101959934-B | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS INC | 2012-12-12 | — | — | CN | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| EP-2520561-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CAI SHAOPEI (US) | 2012-11-01 | — | — | US | disclosed |
| US-8299081-B2 | Methods for treating drug resistant cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8293714-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-23 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
| WO-2012138776-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8222413-B2 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (US) | 2012-07-17 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| CN-101384303-B | Coloring agent for coloring keratin fibers | WELLA AG | 2012-07-04 | — | — | CN | disclosed |
| EP-2007765-B1 | IMMUNOPOTENTIATING COMPOUNDS | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2465857-A1 | Methods for synthesizing heterocyclic compounds | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-20120149710-A1 | SORTASE A INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-06-14 | — | — | US | disclosed |
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120136123-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | SERINA THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-1670787-B1 | CYTOKINE INHIBITORS | ITHERX PHARMA INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-8187992-B2 | Catalyst and method for preparing aromatic carboxylic acids | PROCESS DESIGN CENTER B.V. (NL) | 2012-05-29 | — | — | US | disclosed |
| US-8188309-B2 | Process for preparing aromatic carboxylic acids | PROCESS DESIGN CENTER B.V. (NL) | 2012-05-29 | — | — | US | disclosed |
| WO-2012065021-A1 | DEXAMETHASONE COMBINATION THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120123055-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | SERINA THERAPEUTICS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8173657-B2 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| CN-101495452-B | EP2 agonists | PFIZER PROD INC | 2012-04-25 | — | — | CN | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2012037351-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037349-A2 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20120035200-A1 | GRISEOFULVIN ANALOGUES FOR THE TREATMENT OF CANCER BY INHIBITION OF CENTROSOMAL CLUSTERING | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8110651-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2408773-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8101706-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8088884-B2 | Multi-armed forms of activated polyoxazoline and methods of synthesis thereof | SERINA THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011163636-A2 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2010537-B1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| US-20110301216-A1 | ANTICANCER AND ANTIMICROBIAL COMPOUNDS FROM ANTARCTIC EXTREMOPHILIC MICROORGANSIMS | THE UAB RESEARCH FOUNDATION | 2011-12-08 | — | — | US | disclosed |
| CN-1960731-B | Method for regulating inflammatory and metastatic processes | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2011-12-07 | — | — | CN | disclosed |
| US-20110294019-A1 | ELECTRODE STABILIZING MATERIALS | UCHICAGO ARGONNE, LLC | 2011-12-01 | — | — | US | disclosed |
| US-20110287326-A1 | LONG LIFE LITHIUM BATTERIES WITH STABILIZED ELECTRODES | AMINE KHALIL (US) | 2011-11-24 | — | — | US | disclosed |
| US-8063063-B2 | Immunopotentiating compounds | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| WO-2011143129-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-1888556-B1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| CN-102225926-A | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | NOVARTIS VACCINES & DIAGNOSTIC | 2011-10-26 | — | — | CN | disclosed |
| EP-1656349-B1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2011-10-12 | — | — | EP | disclosed |
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2368908-A2 | Anti- angiogenic compounds | CovX Technologies Ireland Limited (IE) | 2011-09-28 | — | — | EP | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| CN-102164616-A | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-2357184-A1 | Imidazoquinoxaline compounds as immunomodulators | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| CN-1878766-B | Methods for synthesizing quinolinone compounds | NOVARTIS VACCINES & DIAGNOSTIC | 2011-08-17 | — | — | CN | disclosed |
| CN-102149749-A | Polyoxazolines with inert end groups, polyoxazolines prepared from protected initiator groups and related compounds | SERINA THERAPEUTICS INC | 2011-08-10 | — | — | CN | disclosed |
| WO-2011094671-A2 | N-TERMINALLY CONJUGATED POLYPEPTIDES FOR TARGETED THERAPY AND DIAGNOSIS | THE UAB RESEARCH FOUNDATION (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110160266-A1 | Novel Anti-Arrhythmia Agent | THE UAB RESEARCH FOUNDATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-7968235-B2 | non-aqueous electrolyte of an alkali metal salt, a polar aprotic solvent, stabilization additives comprising a metal(chelato)borate such as lithium bis(oxalato) borate (LiBOB) and one or more of an organoamine, an alkane, an alkene, or an aryl compound | UCHICAGO ARGONNE LLC (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2331094-A2 | NOVEL ANTI-ARRHYTHMIA AGENT | The UAB Research Foundation (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110123453-A1 | Polyoxazolines with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds | SERINA THERAPEUTICS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| CN-101160308-B | Pharmaceutically acceptable salts of quinolinone compounds with improved pharmaceutical properties | NOVARTIS VACCINES & DIAGNOSTIC | 2011-05-25 | — | — | CN | disclosed |
| US-7943141-B2 | Activated polyoxazolines and compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| CN-101242876-B | Oxidizing hair coloring agents containing m-aminophenol derivatives | PROCTER & GAMBLE | 2011-05-11 | — | — | CN | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316831-A1 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2310440-A2 | POLYOXAZOLINES WITH INERT TERMINATING GROUPS, POLYOXAZOLINES PREPARED FROM PROTECTED INITIATING GROUPS AND RELATED COMPOUNDS | Serina Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2011-04-14 | — | — | US | disclosed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20110065162-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2295402-A2 | Antibacterial agents | The University of Washington (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2011028492-A2 | SORTASE A INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-2292248-A2 | Anti-angiogenic compounds | CovX Technologies Ireland Limited (IE) | 2011-03-09 | — | — | EP | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| EP-2285415-A1 | ANTI-ANGIOGENIC COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2011-02-23 | — | — | EP | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110028711-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-02-03 | — | — | US | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-101959934-A | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS INC | 2011-01-26 | — | — | CN | disclosed |
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20110009594-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100330023-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | SERINA THERAPEUTICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7858666-B2 | inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides | MANNKIND CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-2258365-A1 | Use of organic compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7842680-B2 | Diene and triene compounds and formulations | HARBOR BIOSCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1497287-B1 | Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7834008-B2 | neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2235090-A2 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | Serina Therapeutics, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249368-A1 | Multi-Armed Forms of Activated Polyoxazoline and Methods of Synthesis Thereof | SERINA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7799808-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| CN-101824034-A | Imidazoquinolie compounds | NOVARTIS VACCINES & DIAGNOSTIC | 2010-09-08 | — | — | CN | disclosed |
| WO-2010096719-A2 | ANTICANCER AND ANTIMICROBIAL COMPOUNDS FROM ANTARCTIC EXTREMOPHILIC MICROORGANISMS | THE UAB RESEARCH FOUNDATION (US) | 2010-08-26 | — | — | WO | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| EP-2204367-A1 | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100144779-A1 | Marine Alkalod Makaluvamines and Derivatives Thereof | THE UAB RESEARCH FOUNDATION (US) | 2010-06-10 | — | — | US | disclosed |
| CN-101056877-B | Imidazoquinoline compounds | NOVARTIS VACCINES & DIAGNOSTIC | 2010-06-09 | — | — | CN | disclosed |
| US-7713989-B2 | Glucocorticoid receptor modulators | DOW ROBERT L | 2010-05-11 | — | — | US | disclosed |
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2170814-A2 | ANTIBACTERIAL AGENTS | Achaogen, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101686687-A | Activated polyoxazolines and compositions containing same | SERINA THERAPEUTICS INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2166018-A2 | Antibody binding affinity ligands | Novo Nordisk A/S (DK) | 2010-03-24 | — | — | EP | disclosed |
| US-20100069579-A1 | Activated Polyoxazolines and Compositions Comprising the Same | SERINA THERAPEUTICS (AL), INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1831243-B1 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK AS (DK) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010025459-A2 | NOVEL ANTI-ARRHYTHMIA AGENT | THE UAB RESEARCH FOUNDATION (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-101663317-A | Glucagon-like protein-1 receptor GLP-1R agonist compounds | COVX TECHNOLOGIES IRELAND LTD | 2010-03-03 | — | — | CN | disclosed |
| US-20100048713-A1 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER | AARHUS UNIVERSITET (DK) | 2010-02-25 | — | — | US | disclosed |
| EP-2155643-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010006282-A2 | POLYOXAZOLINES WITH INERT TERMINATING GROUPS, POLYOXAZOLINES PREPARED FROM PROTECTED INITIATING GROUPS AND RELATED COMPOUNDS | SERINA THERAPEUTICS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7638509-B2 | Diene compounds and formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2134181-A2 | ACTIVATED POLYOXAZOLINES AND COMPOSITIONS COMPRISING THE SAME | Serina Therapeutics, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-101611053-A | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND LTD (IE) | 2009-12-23 | — | — | CN | disclosed |
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| EP-2118131-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| WO-2009136352-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2009-11-12 | — | — | WO | disclosed |
| EP-1313734-B1 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275536-A1 | Antibacterial Agents | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090232844-A1 | IMMUNOPOTENTIATING COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1773880-A4 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090215793-A1 | Methods for treating drug resistant cancer | NOVARTIS AG | 2009-08-27 | — | — | US | disclosed |
| EP-2089425-A2 | ANTI-ANGIOGENIC COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2086925-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-08-12 | — | — | EP | disclosed |
| CN-100526312-C | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| CN-101495452-A | EP2 agonists | PFIZER PROD INC (US) | 2009-07-29 | — | — | CN | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009089542-A2 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181936-A1 | Diene and Triene Compounds and Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090176752-A1 | Diene Compounds and Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-7557100-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-7550450-B2 | Prostate cancer treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-2059507-A2 | EP2 AGONISTS | Pfizer Products Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7521425-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-21 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| US-7514420-B2 | Steroids having 1,8-unsaturation and formulations comprising same | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090088586-A1 | Catalyst and Method For Preparing Aromatic Carboxylic Acids | PROCESS DESIGN CENTER B.V. (NL) | 2009-04-02 | — | — | US | disclosed |
| WO-2009043027-A2 | MULTI-ARMED FORMS OF ACTIVATED POLYOXAZOLINE AND METHODS OF SYNTHESIS THEREOF | SERINA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| CN-101389622-A | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2009-03-18 | — | — | CN | disclosed |
| US-7504405-B2 | Mitotic kinesin inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062563-A1 | Process for Preparing Aromatic Carboxylic Acids | PROCESS DESIGN CENTER B.V. (NL) | 2009-03-05 | — | — | US | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009023160-A2 | NOVEL INHIBITORS OF BACTERIAL SORTASE ENZYMES AND METHODS OF USING THE SAME | THE UAB RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-2010537-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-2007765-A2 | IMMUNOPOTENTIATING COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| EP-1732926-B1 | MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154484-A1 | IRE-1A INHIBITORS | MANNKIND CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080311681-A1 | Antibody Binding Affinity Ligands | VERSAMATRIX A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| US-7462610-B2 | Prostate cancer treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008134630-A1 | DEXRAZOXANE COMPOUNDS FOR CARDIOPROTECTION | APT PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | APT PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| CN-101287485-A | Anti-angiogenic compounds | IRELAND KALVEKS TECHNOLOGY CO (IE) | 2008-10-15 | — | — | CN | disclosed |
| WO-2008120099-A1 | THIENO [3, 2-E] [1, 2] THIAZINE DERIVATIVE AS INHIBITOR OF CARBONIC ANHYDRASE | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | CHIRON CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1976495-A2 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER | Aarhus Universitet (DK) | 2008-10-08 | — | — | EP | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1971612-A1 | 8-PYRAZINYL-S-SPIROPYRIMIDINETRIONE-OXAZINOQUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Pfizer Products Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080213308-A1 | Imidazoquinoline Compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008106186-A2 | ACTIVATED POLYOXAZOLINES AND COMPOSITIONS COMPRISING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-1594524-A4 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008103483-A2 | MARINE ALKALOID MAKALUVAMINES AND DERIVATIVES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1587473-A4 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101222850-A | Methods of treating drug resistant cancers | NOVARTIS AG (CH) | 2008-07-16 | — | — | CN | disclosed |
| CN-101223157-A | Process for the synthesis of heterocyclic compounds | NOVARTIS AG (CH) | 2008-07-16 | — | — | CN | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008081418-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-07-10 | — | — | WO | disclosed |
| US-20080152660-A1 | Anti-Angiogenic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008075152-A1 | 1- [4- (SULFONYL) -PHENYL] -5- (BENZYL) -IH-I, 2, 4-TRIAZOL DERIVATIVES AS INHIBITORS OF CARBONIC ANHYDRASE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075148-A2 | TRICYCLIC INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7390832-B2 | Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment | THE UNIVERSITY OF MARYLAND (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008056346-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-05-15 | — | — | WO | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368455-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7365060-B2 | Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment | UNIVERSITY OF MARYLAND (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| CN-101160308-A | Pharmaceutically acceptable salts of quinolinone compounds with improved pharmaceutical properties | CHIRON CORP (US) | 2008-04-09 | — | — | CN | disclosed |
| US-20080070881-A1 | Prostate Cancer Treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| CN-101146549-A | Antiangiogenic agents and aldesleukin | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-19 | — | — | CN | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1888597-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1650203-B1 | Process of preparation of benzimidazol-2-yl quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888556-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| CN-101124238-A | Antibody binding affinity ligands | NOVO NORDISK AS (DK) | 2008-02-13 | — | — | CN | disclosed |
| WO-2008015517-A2 | EP2 AGONISTS | PFIZER PRODUCTS INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-7326714-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20080009472-A1 | Prostate Cancer Treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080004250-A1 | Compounds and Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1628666-A4 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS INC (US) | 2007-12-05 | — | — | EP | disclosed |
| CN-100351249-C | Quinolinone derivatives as tyrosine kinase inhibitors | CHIRON CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1853302-A2 | ANTIANGIOGENIC AGENTS WITH ALDESLEUKIN | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1853294-A2 | ANTI-ANGIOGENIC COMPOUNDS | Covx Technologies Ireland Limited (IE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| EP-1849782-A1 | Quinolinone derivatives as tyrosine kinase inhibitors | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1843846-A1 | CATALYST AND METHOD FOR PREPARING AROMATIC CARBOXYLIC ACIDS | Process Design Center B. V. (NL) | 2007-10-17 | — | — | EP | disclosed |
| CN-101056877-A | Imidazoquinoline compounds | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-10-17 | — | — | CN | disclosed |
| EP-1838439-A1 | PROCESS FOR PREPARING AROMATIC CARBOXYLIC ACIDS | Process Design Center B. V. (NL) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007109812-A2 | IMMUNOPOTENTIATING COMPOUNDS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109813-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| EP-1831243-A2 | ANTIBODY BINDING AFFINITY LIGANDS | Novo Nordisk A/S (DK) | 2007-09-12 | — | — | EP | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070197518-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2007091140-A1 | SUBSTITUTED PHENYLSULFAMOYL COMPOUNDS AS PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7256196-B1 | Purine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2007-08-14 | — | — | US | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2007-07-26 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007076875-A2 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER | AARHUS UNIVERSITET (DK) | 2007-07-12 | — | — | WO | disclosed |
| EP-1594512-A4 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | KEMIA INC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1497287-A4 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007072151-A1 | 8-PYRAZINYL-S-SPIROPYRIMIDINETRIONE-OXAZINOQUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| EP-1799648-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | Pfizer Products Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1797091-A2 | IMIDAZOQUINOLINE COMPOUNDS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| CN-1984912-A | Mitotic kinesin inhibitors | CHIRON CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20070129410-A1 | Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators | PFIZER INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070117805-A1 | Glucocorticoid receptor modulators | PFIZER INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007053415-A2 | AGENTS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| CN-1960731-A | Method for regulating inflammatory and metastatic processes | CHIRON CORP (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20070088163-A1 | Modulators of calcitonin and amylin activity | KEMIA, INC. | 2007-04-19 | — | — | US | disclosed |
| EP-1773880-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202275-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | WARNER LAMBERT COMPANY LLC (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1768982-A2 | PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1765796-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765313-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1427728-B1 | 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES | PROCTER & GAMBLE (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| EP-1618087-A4 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1732926-A1 | MITOTIC KINESIN INHIBITORS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| CN-1878766-A | Methods for synthesizing quinolinone compounds | CHIRON CORP (US) | 2006-12-13 | — | — | CN | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1725524-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006125130-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| US-7138409-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-7138395-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006120563-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | CHIRON CORPORATION (US) | 2006-11-16 | — | — | US | disclosed |
| EP-1718306-A2 | MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES | Chiron Corporation (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7132539-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060247224-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-11-02 | — | — | US | disclosed |
| US-20060247272-A1 | 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds | PFIZER INC | 2006-11-02 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| WO-2006002422-A9 | COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205670-A1 | Conjugated to antibody; thrombospondin receptor targeting | ZOETIS BELGIUM S.A. (BE) | 2006-09-14 | — | — | US | disclosed |
| EP-1699421-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | Chiron Corporation (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7105543-B2 | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-09-12 | — | — | US | disclosed |
| WO-2006094269-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2006-09-08 | — | — | WO | disclosed |
| CN-1829736-A | severe acute respiratory syndrome coronavirus | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006089150-A2 | ANTIANGIOGENIC AGENTS WITH ALDESLEUKIN | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-7087759-B2 | for controlling weight; pyrrolidine or piperidine compounds | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-7087615-B2 | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1685110-A1 | OCTAHYDROPHENANTHRENE HYDRAZIDE DERIVATIVES USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | disclosed |
| EP-1682529-A2 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | Chiron Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| EP-1427732-B1 | SPIROCYCLIC-6,7-DIHYDRO-5H-PYRAZOLO 1,2-A|PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006066598-A2 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK A/S (DK) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006068472-A1 | PROCESS FOR PREPARING AROMATIC CARBOXYLIC ACIDS | PROCESS DESIGN CENTER B.V. (NL) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006068471-A1 | CATALYST AND METHOD FOR PREPARING AROMATIC CARBOXYLIC ACIDS | PROCESS DESIGN CENTER B.V. (NL) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135553-A1 | Imidazole derivatives | PHENOMIX CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| CN-1787822-A | Compounds and their use in modulating amyloid beta | TORREYPINES THERAPEUTICS INC (US) | 2006-06-14 | — | — | CN | disclosed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | disclosed |
| EP-1201649-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060106059-A1 | Melanocortin receptor ligands | MAZUR WIESLAW A | 2006-05-18 | — | — | US | disclosed |
| EP-1656349-A1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | H. Lundbeck A/S (DK) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006050162-A2 | IMIDAZOLE DERIVATIVES | PHENOMIX CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| US-7041696-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1650203-A1 | Process of preparation of benzimidazol-2-yl quinolinone derivatives | CHIRON CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| US-7026335-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE CO. (US) | 2006-04-11 | — | — | US | disclosed |
| WO-2006033001-A1 | QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033002-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006031878-A2 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | PFIZER INC | 2006-03-23 | — | — | US | disclosed |
| EP-1309586-B1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005121175-A9 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CHIRON CORP (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005016884-A9 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2006-03-16 | — | — | WO | disclosed |
| EP-1628666-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | Torreypines Therapeutics, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060040965-A1 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| US-7001899-B2 | Interleukin converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2006017257-A2 | AZETIDINONE DERIVATIVES | PHENOMIX CORPORATION (US) | 2006-02-16 | — | — | WO | disclosed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1618087-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1618127-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1615944-A2 | ANTIANDROGENS WITH MARGINAL AGONIST ACTIVITY AND METHODS OF USE | Hollis-Eden Pharmaceuticals Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2006004841-A2 | GALANIN AGONISTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006003495-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004703-A2 | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006002422-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20060004022-A1 | 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2006-01-05 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2005121175-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282844-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2005-12-22 | — | — | US | disclosed |
| EP-1607389-A1 | 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors | Pfizer Products Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1601351-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| EP-1148054-B1 | Thyroid receptor ligands | PFIZER PROD INC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1594524-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1317442-B1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1594512-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | Kemia, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | DENINNO MICHAEL P | 2005-11-03 | — | — | US | disclosed |
| CN-1692112-A | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| US-6960604-B2 | Thyroid receptor ligands | PFIZER INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-6960593-B2 | 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005100357-A1 | MITOTIC KINESIN INHIBITORS | CHIRON CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050239835-A1 | Melanocortin receptor ligands | EBETINO FRANK H | 2005-10-27 | — | — | US | disclosed |
| EP-1587473-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6958338-B2 | 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-10-25 | — | — | US | disclosed |
| US-20050228002-A1 | Mitotic kinesin inhibitors | CHIRON CORPORATION (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| WO-2005092845-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1390361-A4 | MELANOCORTIN RECEPTOR LIGANDS | PROCTER & GAMBLE (US) | 2005-10-05 | — | — | EP | disclosed |
| CN-1678285-A | Dyeing method for porous material | CIBA SC HOLDING AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2005-09-22 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| EP-1575940-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005082340-A2 | MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES | CHIRON CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6939867-B2 | Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents | PFIZER INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1201660-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| CN-1659165-A | Quinolinone derivatives | CHIRON CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-0992496-B1 | Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | PFIZER PROD INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050171158-A1 | Melanocortin receptor ligands | EBETINO FRANK H (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-6924310-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1556361-A2 | 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-20050148662-A1 | Dinuclear copper-based and compound and ligand for nucleic acid scission and anticancer treatment | JOHNS HOPKINS UNIVERSITY | 2005-07-07 | — | — | US | disclosed |
| US-20050148610-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-07 | — | — | US | disclosed |
| US-6911447-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050137399-A1 | A lithium-free reaction to produce a substituted/unsubstituted 4-amino-3-benzimidazol-2-yl-quinolin-2-one compound by reacting a 2-aminobenzonitrile with a 2-alkyloxycarbonylmethyl-benzimidazole in a solvent in the presence of a sodium or potassium salt of a base; excellent yields | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050137188-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1539761-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A] PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1114031-B1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6906082-B2 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2005047254-A1 | OCTAHYDROPHENANTHRENE HYDRAZINDE DERIVATIVES USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046589-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046590-A2 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090479-A1 | Dinuclear cooper-based compounds and ligamd for nucleic acid scission and anticancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-28 | — | — | US | disclosed |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-20050075377-A1 | PPAR compounds | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005027931-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AN EP2 OR EP4 SELECTIVE AGONIST | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | PFIZER INC | 2005-03-24 | — | — | US | disclosed |
| WO-2005025504-A2 | MODULATORS OF CALCITONIN AND AMYLIN ACTIVITY | KEMIA, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1513844-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1511491-A1 | DERIVATIVES OF AZEPINE AND THIAZEPAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511749-A1 | NOVEL INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005016884-A1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20050026897-A1 | Trinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment | UNIVERSITY OF MARYLAND | 2005-02-03 | — | — | US | disclosed |
| US-6849627-B2 | Including interleukin-1 and Tumor Necrosis Factor; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, septic shock, cardiopulmonary dysfunction, acute respiratory disease, and cachexia | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050019670-A1 | Long life lithium batteries with stabilized electrodes | U CHICAGO ARGONNE LLC | 2005-01-27 | — | — | US | disclosed |
| EP-1499588-A1 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1499314-A1 | N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS | The Procter & Gamble Company (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1427727-B1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1499317-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | Pfizer Products Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1497287-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20050010031-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2005-01-13 | — | — | US | disclosed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| EP-1485167-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | The Procter & Gamble Company (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040248850-A1 | Compounds for the treatment of HIV infection | KEMIA, INC. | 2004-12-09 | — | — | US | disclosed |
| US-6828343-B2 | For therapy and prophylaxis of atherosclerosis, diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, hyperglycemia | PFIZER, INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040241192-A1 | Use of tryptanthrin compounds for immune potentiation | CHIRON CORPORATION (US) | 2004-12-02 | — | — | US | disclosed |
| US-20040242618-A1 | Antiandrogens with marginal agonist activity and methods of use | BIOVIE INC. | 2004-12-02 | — | — | US | disclosed |
| EP-1478437-A1 | ACC INHIBITORS | Pfizer Products Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6821971-B2 | FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA | THE PROCTER & GAMBLE COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| US-20040224985-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2004-11-11 | — | — | US | disclosed |
| CN-1543334-A | Oxidation hair dye agent comprising 3-aminophenol derivative and novel 3-aminophenol derivative | P&G | 2004-11-03 | — | — | CN | disclosed |
| WO-2004091542-A2 | NITROGEN CONTAINING INTEGRIN TARGETING COMPOUNDS | COVX PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004089304-A2 | ANTIANDROGENS WITH MARGINAL AGONIST ACTIVITY AND METHODS OF USE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| US-6800760-B2 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| EP-1114033-B1 | 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1458714-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004078169-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004074256-A1 | TETRAHYDROISOQUINOLINYL SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
| WO-2004071426-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTION | KEMIA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-6774237-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES INHIBITORS; ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS | CHIRON CORPORATION | 2004-08-10 | — | — | US | disclosed |
| WO-2004064759-A2 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | CHIRON CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-6762194-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | CHIRON CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6759417-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS; SUCH AS 7-AMINO-6-(1H-BENZIMIDAZOL-2-YL)-3,4-DIHYDRO-5H-IMIDAZO(4,5-B)PYRIDIN-5-ONE | CHIRON CORPORATION | 2004-07-06 | — | — | US | disclosed |
| US-6756383-B2 | SUCH AS 3-(2-(METHOXYCARBONYL)ACETYLAMINO)PYRIDINE-4-CARBOXYLIC ACID FOR TREATMENT OF DISEASES CHARACTERIZED BY ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES; ENZYME INHIBITORS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1427728-A1 | 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1427732-A1 | SPIROCYCLIC-6,7-DIHYDRO-5H-PYRAZOLO 1,2-A]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040110951-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-06-10 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-1114032-B1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2004-06-02 | — | — | EP | disclosed |
| US-6743809-B2 | Indole Derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | disclosed |
| US-20040097545-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2004-05-20 | — | — | US | disclosed |
| EP-0987251-B1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040087639-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia | THE PROCTER & GAMBLE COMPANY | 2004-05-06 | — | — | US | disclosed |
| WO-2004037797-A2 | 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1305307-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-6730668-B2 | PREVENTING EXTRACELLULAR RELEASE | THE PROCTER & GAMBLE COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-04-22 | — | — | US | disclosed |
| WO-2004026878-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20040058944-A1 | 6,7-Dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones whinch control inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2004-03-25 | — | — | US | disclosed |
| CN-1483028-A | Quinolinone derivatives as tyrosine kinase inhibitors | ϣ | 2004-03-17 | — | — | CN | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | disclosed |
| US-20040038971-A1 | 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
| EP-1391460-A1 | Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1390361-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6696605-B2 | CATALYTICALLY REACTING POLYMER SUPPORTED ISOCYANIDE WITH ALDEHYDE; OPTIONALLY OXIDIZING; CLEAVING NITROGEN RESIN BOND | THE PROCTER & GAMBLE COMPANY | 2004-02-24 | — | — | US | disclosed |
| US-20040018983-A1 | Antifungal compositions | ACHILLION PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-20040009966-A1 | 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis | THE PROCTER & GAMBLE COMPANY | 2004-01-15 | — | — | US | disclosed |
| US-20040010010-A1 | Melanocortin receptor ligands | PROCTER & GAMBLE COMPANY, THE | 2004-01-15 | — | — | US | disclosed |
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20040006101-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2004-01-08 | — | — | US | disclosed |
| EP-1088824-B1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20040002518-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-20030236230-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003106460-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003103677-A1 | DERIVATIVES OF AZEPINE AND THIAZERAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6664291-B2 | Aromatic amidealkyl acid or ester or amide or hydroxy derivatives are useful in the treatment of obesity, overweight condition, hyperlipidemia, glucoma, cardiac arrhythmias, thyroid disease, skin disoders and diabetes | PFIZER, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | disclosed |
| US-6649657-B2 | Administering amide to treat osteoporosis | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| WO-2003092690-A1 | N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003092694-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| WO-2003093234-A1 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1360172-A1 | PPAR AGONISTS | Pfizer Products Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| WO-2003087095-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003080184-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030176739-A1 | Process for preparing alpha-hydroxyamides and alpha-ketoamides on a solid phase support | THE PROCTER & GAMBLE COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-6620830-B2 | Certain thiazolidinedione, oxadiazolidinedione, and triazolone compounds which are thyroid receptor ligands | PFIZER, INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030166665-A1 | 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166664-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003072197-A1 | ACC INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003070712-A1 | THIOIBOTENIC ACID AND DERIVATIVES THEREOF | H. LUNDBECK A/S (DK) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | disclosed |
| US-20030134867-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-07-17 | — | — | US | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003055448-A2 | ANTIFUNGAL COMPOSITIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003054145-A2 | DINUCLEAR COPPER-BASED COMPOUND AND LIGAND FOR NUCLEIC ACID SCISSION AND ANTICANCER TREATMENT | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6586448-B1 | Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2003052058-A2 | DINUCLEAR COPPER-BASED COMPOUND AND LIGAND FOR NUCLEIC ACID SCISSION AND ANTICANCER TREATMENT | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051869-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. LUNDBECK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| US-20030109556-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6576653-B2 | For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis | PFIZER INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLEY Q (US) | 2003-06-05 | — | — | US | disclosed |
| EP-1313734-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6566357-B1 | To inhibit the extracellular release of inflammatory cytokines; therapy | THE PROCTER & GAMBLE CO. | 2003-05-20 | — | — | US | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1309586-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-05-14 | — | — | EP | disclosed |
| EP-1305307-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. Lundbeck A/S (DK) | 2003-05-02 | — | — | EP | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| WO-2003024973-A1 | SPIROCYCLIC-6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024971-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | disclosed |
| US-6531485-B2 | For therapy of bone disorders including osteoporosis | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | ASPNES GARY E (US) | 2003-02-27 | — | — | US | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-20030008895-A1 | PROSTAGLANDIN AGONISTS | CAMERON KIMBERLY O (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1268404-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6492412-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | disclosed |
| US-6489478-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INHIBITORS AND THE USE OF SUCH INHIBITORS TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN | PFIZER INC. | 2002-12-03 | — | — | US | disclosed |
| WO-2002095050-A2 | TRINUCLEAR COPPER-BASED COMPOUND AND LIGAND FOR NUCLEIC ACID SCISSION AND ANTICANCER TREATMENT | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020169192-A1 | PPAR compounds | HAYWARD CHERYL M (US) | 2002-11-14 | — | — | US | disclosed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | disclosed |
| US-20020165255-A1 | Osteoporosis compounds | CAMERON KIMBERLY O (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002085925-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| EP-1065206-B1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6441015-B2 | OBESITY, ANTIDIABETIC AGENTS, CARDIOVASCULAR DISORDERS | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002064549-A1 | PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | disclosed |
| US-6395751-B1 | SYNERGISTIC MIXTURE; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6376502-B1 | PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6362198-B1 | ANTICHOLESTEROL, ANTILIPEMIC AGENT | PFIZER INC. | 2002-03-26 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2002018383-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002016349-A1 | 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | disclosed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | disclosed |
| WO-2002008223-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-31 | — | — | WO | disclosed |
| EP-1175383-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | disclosed |
| US-20010051645-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2001-12-13 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| US-6310075-B1 | COMBINATION OF COMPOUNDS TO TREAT ATHEROSCLEROSIS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| CN-1309561-A | Therapeutic agent for erectile dysfunction | MOCHIDA PHARM CO LTD (JP) | 2001-08-22 | — | — | CN | disclosed |
| EP-1114031-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1114032-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1099442-A2 | Methods of administering apo B-secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| US-6147090-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS USED TO TREAT DISEASES WHICH ARE EXACERBATED BY LOW LEVELS OF HDL CHOLESTEROL AND/OR HIGH LEVELS OF LDL-CHOLESTEROL AND TRIGLYCERIDES, SUCH AS ATHEROSCLEROSIS AND CARDIOVASCULAR | PFIZER INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6147089-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS USED TO TREAT DISEASES WHICH ARE EXACERBATED BY LOW LEVELS OF HDL CHOLESTEROL AND/OR HIGH LEVELS OF LDL-CHOLESTEROL AND TRIGLYCERIDES, SUCH AS ATHEROSCLEROSIS AND CARDIOVASCULAR | PFIZER INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000066522-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6140342-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR; USED TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN OTHER PLASMA LIPID LEVELS, SUCH AS LDL-CHOLESTEROL AND TRIGLYCERIDES | PFIZER INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0992496-A1 | Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000017165-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017164-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0987251-A1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998058911-A2 | PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5739130-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS, MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0639182-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | disclosed |
| WO-1992018483-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018483-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | TRPA1 615/4885ITGB2 639/4885ICAM1 4248/4885 |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | TRPA1 3625/4885ITGB2 3122/4885ICAM1 3071/4885 |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | TRPA1 4083/4885ITGB2 4111/4885ICAM1 3688/4885 |
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | TRPA1 950/4885ITGB2 2855/4885ICAM1 3752/4885 |
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | KIF5B, KIF2C, KIFC1 | TRPA1 4795/4885ITGB2 4522/4885ICAM1 3584/4885 |
| US-20140275591-A1 | NOVEL COMPOUNDS | SGMS2, SGMS1, SMPD1 | TRPA1 4274/4885ITGB2 3536/4885ICAM1 4718/4885 |
| US-20040248850-A1 | Compounds for the treatment of HIV infection | CCR5, CD4, HAVCR2 | TRPA1 4040/4885ITGB2 3063/4885ICAM1 236/4885 |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | TRPA1 269/4885ITGB2 1198/4885ICAM1 3052/4885 |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | TRPA1 3625/4885ITGB2 3122/4885ICAM1 3071/4885 |
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | TRPA1 183/4885ITGB2 1768/4885ICAM1 3621/4885 |
| US-20080070881-A1 | Prostate Cancer Treatment | AR, KLK3, PTGER1 | TRPA1 3692/4885ITGB2 2364/4885ICAM1 920/4885 |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | TRPA1 3666/4885ITGB2 3529/4885ICAM1 2241/4885 |
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | TRPA1 3430/4885ITGB2 3613/4885ICAM1 4539/4885 |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | TRPA1 3625/4885ITGB2 3122/4885ICAM1 3071/4885 |
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | TRPA1 3595/4885ITGB2 4189/4885ICAM1 1967/4885 |
| US-20160317673-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | ERBB3, ERBB2, PANK2 | TRPA1 4860/4885ITGB2 162/4885ICAM1 3854/4885 |
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | TRPA1 911/4885ITGB2 2919/4885ICAM1 1590/4885 |
| US-20050010031-A1 | Melanocortin receptor ligands | MC3R, MC5R, MC1R | TRPA1 848/4885ITGB2 1780/4885ICAM1 4092/4885 |
| US-20220193243-A1 | MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME | ERBB3, ERBB2, PANK2 | TRPA1 4860/4885ITGB2 162/4885ICAM1 3854/4885 |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | TRPA1 769/4885ITGB2 3036/4885ICAM1 4110/4885 |
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | TRPA1 741/4885ITGB2 2853/4885ICAM1 2921/4885 |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | TRPA1 4570/4885ITGB2 4206/4885ICAM1 2339/4885 |
| US-20140371227-A1 | KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | TRPA1 1738/4885ITGB2 1621/4885ICAM1 3519/4885 |
| US-20060040965-A1 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | LCK, ADCK1, DCK | TRPA1 3078/4885ITGB2 3679/4885ICAM1 4603/4885 |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | TRPA1 3826/4885ITGB2 3778/4885ICAM1 4578/4885 |
| US-20130123230-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | TRPA1 2787/4885ITGB2 2841/4885ICAM1 1208/4885 |
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | HEXD, SORD, SDHA | TRPA1 4345/4885ITGB2 4336/4885ICAM1 3557/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | TRPA1 4266/4885ITGB2 4159/4885ICAM1 3632/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | TRPA1 3716/4885ITGB2 3208/4885ICAM1 4324/4885 |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, PPARD | TRPA1 1253/4885ITGB2 4249/4885ICAM1 3351/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | TRPA1 3430/4885ITGB2 3613/4885ICAM1 4539/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | TRPA1 468/4885ITGB2 2208/4885ICAM1 4626/4885 |
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | TRPA1 2511/4885ITGB2 1937/4885ICAM1 50/4885 |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | TRPA1 2775/4885ITGB2 4664/4885ICAM1 3317/4885 |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | SORD, HEXD, SDHA | TRPA1 4391/4885ITGB2 4497/4885ICAM1 3873/4885 |
| US-20030109556-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | TRPA1 915/4885ITGB2 1562/4885ICAM1 3106/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | TRPA1 3592/4885ITGB2 3863/4885ICAM1 1620/4885 |
| US-20100330023-A1 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same | ERBB3, ERBB2, PANK2 | TRPA1 4860/4885ITGB2 162/4885ICAM1 3854/4885 |
| US-20190315822-A1 | Growth Differentiation Factor 15 (GDF-15) Polypeptides | IGFBP5, IGFBP2, IGFBP1 | TRPA1 4740/4885ITGB2 4057/4885ICAM1 3249/4885 |
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | KCNJ2, KCNQ2, KCNJ11 | TRPA1 1929/4885ITGB2 4248/4885ICAM1 4868/4885 |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3CD, PIK3CG | TRPA1 4513/4885ITGB2 2753/4885ICAM1 4422/4885 |
| US-20130310352-A1 | DEXAMETHASONE COMBINATION THERAPY | NR3C2, NR3C1, HSD11B1 | TRPA1 4242/4885ITGB2 4435/4885ICAM1 3527/4885 |
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | TNNT2, TNNI3, TNNC1 | TRPA1 1142/4885ITGB2 1157/4885ICAM1 2781/4885 |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | TRPA1 4260/4885ITGB2 4806/4885ICAM1 2049/4885 |
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, NR1H2 | TRPA1 4787/4885ITGB2 3558/4885ICAM1 928/4885 |
| US-20050148662-A1 | Dinuclear copper-based and compound and ligand for nucleic acid scission and anticancer treatment | DDB1, POLN, DNASE1 | TRPA1 4315/4885ITGB2 4247/4885ICAM1 3396/4885 |
| US-20160024001-A1 | NOVEL COMPOUNDS | SGMS1, SGMS2, UGCG | TRPA1 4270/4885ITGB2 4278/4885ICAM1 4753/4885 |
| US-20040087639-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia | OPRK1, OPRD1, IL1B | TRPA1 553/4885ITGB2 1076/4885ICAM1 556/4885 |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | TRPA1 4266/4885ITGB2 4159/4885ICAM1 3632/4885 |
| US-20120149710-A1 | SORTASE A INHIBITORS | STS, ENGASE, SPR | TRPA1 3476/4885ITGB2 2723/4885ICAM1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.